Leif Johansson, chairman of pharmaceutical group AstraZeneca, has addressed in an interview to Handelsblatt the aftermaths of Brexit in the pharma sector. Johansson, 66, from Sweden, MSc in mechanical engineering and former chairman of Ericsson group, has said that AstraZeneca will no longer invest in production sites or output increase in Britain due to Brexit. However, AstraZeneca will invest in R&D, because Britain has centers of excellence for the development of novel drugs. Should the UK and Europe fail to reach an agreement, AstraZeneca would even risk not being able to import drugs produced abroad to the UK because of WTO restrictions, the Swedish manager has said. Importantly, AstraZeneca is about to open a new facility in Cambridge Biomedical Campus, which has cost £500m and will employ a minimum of 2,000 employees.